As filed with the Securities and Exchange Commission on February 22, 2024
Registration No. 333-
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM S-8
REGISTRATION STATEMENT
UNDER
THE SECURITIES ACT OF 1933
Intellia Therapeutics, Inc.
(Exact name of registrant as specified in its charter)
| Delaware | 001-37766 | 36-4785571 | ||
| (State or Other Jurisdiction of Incorporation) | (Commission File Number) | (IRS Employer Identification No.) | ||
| 40 Erie Street, Suite 130 | ||||
| Cambridge, Massachusetts | 02139 | |||
| (Address of Principal Executive Offices) | (Zip Code) | |||
Intellia Therapeutics, Inc. 2015 Amended and Restated Stock Option and Incentive Plan
(Full title of the plan)
John Leonard, M.D.
President and Chief Executive Officer
40 Erie Street, Suite 130
Cambridge, Massachusetts 02139
(857) 285-6200
(Name, address and telephone number, including area code, of agent for service)
Copies to:
Michael H. Bison, Esq. Gabriela Morales-Rivera, Esq. Goodwin Procter LLP 100 Northern Ave. Boston, Massachusetts 02210 (617) 570-1000 | James Basta, Esq. Executive Vice President, General Counsel Intellia Therapeutics, Inc. 40 Erie Street, Suite 130 Cambridge, Massachusetts 02139 (857) 285-6200 |
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
| Large accelerated filer | ☒ | Accelerated filer | ☐ | |||
| Non-accelerated filer | ☐ | Smaller reporting company | ☐ | |||
| Emerging growth company | ☐ | |||||
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐
Statement of Incorporation by Reference
This Registration Statement on Form S-8 is filed to register the offer and sale of an additional 3,719,886 shares of the Registrant’s common stock, $0.0001 par value per share, to be issued under the Registrant’s Amended and Restated 2015 Stock Option and Incentive Plan.
Pursuant to General Instruction E to Form S-8, the contents of the Registration Statements on Form S-8 filed by the Registrant on May 6, 2016 (File No. 333-211200), June 5, 2017 (File No 333-218511) February 27, 2019 (File No. 333-229900), February 27, 2020 (File No. 333-236714), February 26, 2021 (File No. 333-253562), February 24, 2022 (File No. 333-262997), and February 23, 2023 (File No. 333-269947), related to the Registrant’s Amended and Restated 2015 Stock Option and Incentive Plan are incorporated by reference, except to the extent supplemented, amended or superseded by the information set forth herein. Only those items of Form S-8 containing new information not contained in the earlier Registration Statements are presented herein.
Part II
Information Required in the Registration Statement
Item 8. Exhibits.
See the Exhibit Index below for a list of exhibits filed as part of this registration statement on Form S-8, which Exhibit Index is incorporated herein by reference.
EXHIBIT INDEX
| * | Filed herewith. |
SIGNATURES
Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Cambridge, Commonwealth of Massachusetts, on this 22nd day of February, 2024.
| INTELLIA THERAPEUTICS, INC. | ||
| By: | /s/ John Leonard | |
| John Leonard, M.D. | ||
| President and Chief Executive Officer | ||
POWER OF ATTORNEY AND SIGNATURES
KNOW ALL BY THESE PRESENT, that each individual whose signature appears below hereby constitutes and appoints each of John Leonard, M.D., James Basta, J.D. and Glenn Goddard as such person’s true and lawful attorney-in-fact and agent with full power of substitution and resubstitution, for such person in such person’s name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement on Form S-8, and to file the same, with all exhibits thereto, and all documents in connection therewith, with the Securities and Exchange Commission granting unto each said attorney-in-fact and agent full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as such person might or could do in person, hereby ratifying and confirming all that any said attorney-in-fact and agent, or any substitute or substitutes of any of them, may lawfully do or cause to be done by virtue hereof.
Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed by the following person in the capacities and on the date indicated.
| Name | Title | Date | ||
/s/ John Leonard | President, Chief Executive Officer and Director | February 22, 2024 | ||
| John Leonard, M.D. | (Principal Executive Officer) | |||
/s/ Glenn Goddard | Executive Vice President, Chief Financial Officer | February 22, 2024 | ||
| Glenn Goddard | (Principal Financial and Accounting Officer) | |||
/s/ Fred Cohen | Director | February 22, 2024 | ||
| Fred Cohen, M.D., D.Phil. | ||||
/s/ Bill Chase | Director | February 22, 2024 | ||
| Bill Chase | ||||
/s/ Jesse Goodman | Director | February 22, 2024 | ||
| Jesse Goodman, M.D. | ||||
/s/ Georgia Keresty | Director | February 22, 2024 | ||
| Georgia Keresty, Ph.D. | ||||
/s/ Frank Verwiel | Director | February 22, 2024 | ||
| Frank Verwiel, M.D. | ||||
/s/ Muna Bhanji | Director | February 22, 2024 | ||
| Muna Bhanji, R.Ph. | ||||
